Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:DYAX
CUSIP26746E10
Phone+1-617-2505769
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-47.32%
Return on Equity-14.86%
Return on Assets-12.09%
Miscellaneous
EmployeesN/A
Outstanding Shares146,360,000
Dyax (NASDAQ:DYAX) Frequently Asked Questions
What is Dyax's stock symbol?
Dyax trades on the NASDAQ under the ticker symbol "DYAX."
How were Dyax's earnings last quarter?
Dyax Corp. (NASDAQ:DYAX) announced its quarterly earnings data on Wednesday, October, 28th. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.08). The biopharmaceutical company earned $24.70 million during the quarter, compared to analysts' expectations of $24.96 million. Dyax had a negative net margin of 47.32% and a negative return on equity of 14.86%. The business's revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter last year, the business earned ($0.01) earnings per share. View Dyax's Earnings History.
Has Dyax been receiving favorable news coverage?
Media headlines about DYAX stock have trended very positive recently, Accern Sentiment reports. The research firm scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dyax earned a news sentiment score of 0.70 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 43.66 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Dyax?
Shares of DYAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dyax's stock price today?
One share of DYAX stock can currently be purchased for approximately $38.41.
How can I contact Dyax?
Dyax's mailing address is 55 Network Dr, BURLINGTON, MA 01803-2756, United States. The biopharmaceutical company can be reached via phone at +1-617-2505769.
MarketBeat Community Rating for Dyax (DYAX)
MarketBeat's community ratings are surveys of what our community members think about Dyax and other stocks. Vote "Outperform" if you believe DYAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DYAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
